<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02823249</url>
  </required_header>
  <id_info>
    <org_study_id>fMRI Aminoacids</org_study_id>
    <nct_id>NCT02823249</nct_id>
  </id_info>
  <brief_title>Effect of Amino Acids and Sugar Alcohols on Satiation Peptides and Activation of Specific Brain Regions</brief_title>
  <official_title>Effect of Amino Acids and Sugar Alcohols on Release of Satiation Peptides and Activation of Specific Brain Regions in Normal Weight and Obese Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Basel, Switzerland</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Basel, Switzerland</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      With this study the investigators investigate the effects of amino acids (tryptophan, leucin)
      and sugar alcohols (xylitol, erythritol) on satiety mechanisms and brain activation.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2014</start_date>
  <completion_date type="Actual">April 2015</completion_date>
  <primary_completion_date type="Actual">April 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Effect of aminoacids on cerebral blood flow measured by functional brain MRI</measure>
    <time_frame>changes from baseline to one hour after treatment</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Effect of sugar alcohols on cerebral blood flow measured by functional brain MRI</measure>
    <time_frame>changes from baseline to one hour after treatment</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Measurement of Plasma Glucose concentrations</measure>
    <time_frame>changes from baseline to three hours after treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measurement of Plasma Insulin concentrations</measure>
    <time_frame>changes from baseline to three hours after treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measurement of Plasma cholecystokinin concentrations</measure>
    <time_frame>changes from baseline to three hours after treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measurement of Plasma Glucagon-like Peptide (GLP-1) concentrations</measure>
    <time_frame>changes from baseline to three hours after treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measurement of Plasma PYY concentrations</measure>
    <time_frame>changes from baseline to three hours after treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measurement of Plasma ghrelin concentrations</measure>
    <time_frame>changes from baseline to three hours after treatment</time_frame>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Endocrine System Diseases</condition>
  <arm_group>
    <arm_group_label>1.56 g L-Tryptophan</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>1.56 g L-Tryptophan in 300 mL tap water given via nasogastric tube
+ after 60 min: 500ml of a mixed liquid meal (Ensure Plus®; 17% protein, 29% fat and 54% carbohydrate) given via nasogastric tube</description>
  </arm_group>
  <arm_group>
    <arm_group_label>1.56 g L-Leucine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>1.56 g L-Leucine in 300 mL tap water given via nasogastric tube
+ after 60 min: 500ml of a mixed liquid meal (Ensure Plus®; 17% protein, 29% fat and 54% carbohydrate) given via nasogastric tube</description>
  </arm_group>
  <arm_group>
    <arm_group_label>50 g Xylitol</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>50 g Xylitol in 300 mL tap water given via nasogastric tube</description>
  </arm_group>
  <arm_group>
    <arm_group_label>75 g Erythritol</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>75 g Erythritol in 300 mL tap water given via nasogastric tube</description>
  </arm_group>
  <arm_group>
    <arm_group_label>75 g Glucose and mixed liquid meal</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>75 g Glucose in 300 mL tap water given via nasogastric tube
+ after 60 min: 500ml of a mixed liquid meal (Ensure Plus®; 17% protein, 29% fat and 54% carbohydrate) given via nasogastric tube</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Tap water and mixed liquid meal</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>300 mL tap water given via nasogastric tube
+ after 60 min: 500ml of a mixed liquid meal (Ensure Plus®; 17% protein, 29% fat and 54% carbohydrate) given via nasogastric tube</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>1.56 g L-Tryptophan</intervention_name>
    <arm_group_label>1.56 g L-Tryptophan</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>1.56 g L-Leucine</intervention_name>
    <arm_group_label>1.56 g L-Leucine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>50 g Xylitol</intervention_name>
    <arm_group_label>50 g Xylitol</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>75 g Erythritol</intervention_name>
    <arm_group_label>75 g Erythritol</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>75 g Glucose</intervention_name>
    <arm_group_label>75 g Glucose and mixed liquid meal</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Tap water</intervention_name>
    <arm_group_label>1.56 g L-Tryptophan</arm_group_label>
    <arm_group_label>1.56 g L-Leucine</arm_group_label>
    <arm_group_label>50 g Xylitol</arm_group_label>
    <arm_group_label>75 g Erythritol</arm_group_label>
    <arm_group_label>75 g Glucose and mixed liquid meal</arm_group_label>
    <arm_group_label>Tap water and mixed liquid meal</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Mixed liquid meal (Ensure Plus®; 17% protein, 29% fat and 54% carbohydrate)</intervention_name>
    <arm_group_label>1.56 g L-Tryptophan</arm_group_label>
    <arm_group_label>1.56 g L-Leucine</arm_group_label>
    <arm_group_label>75 g Glucose and mixed liquid meal</arm_group_label>
    <arm_group_label>Tap water and mixed liquid meal</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Nasogastric Tube</intervention_name>
    <arm_group_label>1.56 g L-Tryptophan</arm_group_label>
    <arm_group_label>1.56 g L-Leucine</arm_group_label>
    <arm_group_label>50 g Xylitol</arm_group_label>
    <arm_group_label>75 g Erythritol</arm_group_label>
    <arm_group_label>75 g Glucose and mixed liquid meal</arm_group_label>
    <arm_group_label>Tap water and mixed liquid meal</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy normal weight subjects with a body-mass index of 19.0-24.9

          -  Healthy obese subjects with a body-mass index of &gt; 30

          -  Normal eating habits (no diets; no dietary changes; no special dietary habits such as
             vegetarian/vegan)

          -  Age 18-40 years

          -  Stable body weight for at least three months

        Exclusion Criteria:

          -  Smoking

          -  Substance abuse

          -  Regular intake of medications (except for oral contraceptives)

          -  Medical or psychiatric illness

          -  History of gastrointestinal disorders

          -  Food allergies

          -  Pregnancy, breast feeding

          -  Body piercings that cannot be removed

          -  History of claustrophobia

          -  Left-hander
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christoph Beglinger, Prof.</last_name>
    <role>Study Chair</role>
    <affiliation>University Hospital, Basel, Switzerland</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University Hospital Basel</name>
      <address>
        <city>Basel</city>
        <state>Basel-Stadt</state>
        <zip>4031</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>February 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 27, 2016</study_first_submitted>
  <study_first_submitted_qc>July 5, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 6, 2016</study_first_posted>
  <last_update_submitted>February 26, 2017</last_update_submitted>
  <last_update_submitted_qc>February 26, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">February 28, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Endocrine System Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tryptophan</mesh_term>
    <mesh_term>Erythritol</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

